Prevalence Rates of Amyloid Positivity—Updates and Relevance

Young and Mormino discuss the prevalence rates of amyloid positivity. The field of biomarker research in Alzheimer disease (AD) has exploded over the past 2 decades, with tens of thousands of individuals undergoing characterization of amyloid burden with cerebrospinal fluid (CSF) and/or positron emission tomography (PET). On the basis of amyloid PET data, the US Food and Drug Administration approved aducanumab in June 2021; it is the first disease-modifying treatment of AD that substantially reduces amyloid plaque buildup in the brain. Knowledge of amyloid status has also been shown to change care in the clinical setting.